VIA E-MAILMersana Therapeutics, Inc. • May 9th, 2022 • Pharmaceutical preparations • Massachusetts
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. RESEARCH COLLABORATION...Research Collaboration and License Agreement • May 9th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
MERSANA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 840 Memorial Drive Cambridge, MA 02139 (hereinafter referred to as “Mersana”)
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO LOAN...Loan and Security Agreement • May 9th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of February 17, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 275 Grove Street, Suite 2-200, Newton, MA 02466 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and MERSANA THERAPEUTICS, INC., a Delaware corporation with offices located at 840 Memorial Drive, Cambridge, MA 02139 (“Borrower”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Amendment #1 to the...License and Option Agreement • May 9th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment #1 (this "Amendment") dated February 2, 2022 (the "Amendment Effective Date"), is made by and between Mersana Therapeutics, Inc., with an office at 840 Memorial Drive, Cambridge, Massachusetts, 02139, USA (hereinafter referred to as "MERSANA") and Synaffix B.V., with business address at Kloosterstraat 9, 5349 AB Oss, The Netherlands ("SNFX"); COMPANY and SNFX hereinafter individually referred to as “Party” and jointly as “Parties”.
